
Brain and Whole-Body Imaging of Nociceptin/Orphanin FQ Peptide Receptor in Humans Using the PET Ligand ^{11}C -NOP-1A

Talakad G. Lohith¹, Sami S. Zoghbi¹, Cheryl L. Morse¹, Maria F. Araneta¹, Vanessa N. Barth², Nancy A. Goebel², Johannes T. Tauscher², Victor W. Pike¹, Robert B. Innis¹, and Masahiro Fujita¹

¹Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; and ²Eli Lilly & Co., Indianapolis, Indiana

Nociceptin/orphanin FQ peptide (NOP) receptor is a new class of opioid receptor that may play a pathophysiologic role in anxiety and drug abuse and is a potential therapeutic target in these disorders. We previously developed a high-affinity PET ligand, ^{11}C -NOP-1A, which yielded promising results in monkey brain. Here, we assessed the ability of ^{11}C -NOP-1A to quantify NOP receptors in human brain and estimated its radiation safety profile.

Methods: After intravenous injection of ^{11}C -NOP-1A, 7 healthy subjects underwent brain PET for 2 h and serial sampling of radial arterial blood to measure parent radioligand concentrations. Distribution volume (V_T ; a measure of receptor density) was determined by compartmental (1- and 2-tissue) and noncompartmental (Logan analysis and Ichise's bilinear analysis [MA1]) methods. A separate group of 9 healthy subjects underwent whole-body PET to estimate whole-body radiation exposure (effective dose). **Results:** After ^{11}C -NOP-1A injection, the peak concentration of radioactivity in brain was high (~5–7 standardized uptake values), occurred early (~10 min), and then washed out quickly. The unconstrained 2-tissue-compartment model gave excellent V_T identifiability (~1.1% SE) and fitted the data better than a 1-tissue-compartment model. Regional V_T values ($\text{mL}\cdot\text{cm}^{-3}$) ranged from 10.1 in temporal cortex to 5.6 in cerebellum. V_T was well identified in the initial 70 min of imaging and remained stable for the remaining 50 min, suggesting that brain radioactivity was most likely parent radioligand, as supported by the fact that all plasma radiometabolites of ^{11}C -NOP-1A were less lipophilic than the parent radioligand. Voxel-based MA1 V_T values correlated well with results from the 2-tissue-compartment model, showing that parametric methods can be used to compare populations. Whole-body scans showed radioactivity in brain and in peripheral organs expressing NOP receptors, such as heart, pancreas, and spleen. ^{11}C -NOP-1A was significantly metabolized and excreted via the hepatobiliary route. Gallbladder had the highest radiation exposure (21 $\mu\text{Sv}/\text{MBq}$), and the effective dose was 4.3 $\mu\text{Sv}/\text{MBq}$. **Conclusion:** ^{11}C -NOP-1A is a promising radioligand that reliably quantifies NOP receptors in human brain. The effective dose in humans is low and similar to that of other ^{11}C -labeled radioligands, allowing multiple scans in 1 subject.

Key Words: NOP receptors; nociceptin; opioid receptor; PET; receptor imaging

J Nucl Med 2012; 53:385–392

DOI: 10.2967/jnumed.111.097162

The nociceptin/orphanin FQ peptide (NOP) receptor was cloned as an orphan receptor with no known endogenous transmitter (1). Subsequently, NOP itself was discovered as a 17-amino-acid peptide with sequence similarities to endogenous opioid peptide dynorphin A (2). The NOP receptor is coupled to the G-protein G_i/G_o , inhibits the production of cyclic adenosine monophosphate, activates potassium channels, and inhibits calcium channels. Although the NOP receptor shares some amino acid sequence similarities with the classic opiate receptor, the mechanism of action of the NOP transmitter could not be blocked by the opioid antagonist naloxone; thus, the NOP receptor is considered a nonopiate member of the opioid receptor family (3).

NOP receptors are widely distributed in brain, spinal cord, heart, lungs, kidneys, intestine, and immune cells of different mammalian species, where they mediate the actions of endogenous peptides in a complex manner. For example, animal studies suggest that NOP receptor activation in the periphery reduces pain perception, but similar activation in the brain increases pain perception (3). In addition, NOP receptors may mediate both the consumption of alcohol and anxiety-related behaviors. Elevated NOP receptor messenger RNA levels, as well as increased ^3H -nociceptin binding in central amygdala, were both noted in Marchigian Sardinian alcohol-preferring rats (4). NOP receptor agonists were also shown to have an anxiolytic effect across multiple species (5). As a result, investigators have focused on developing NOP receptor ligands for therapeutic trials in humans.

PET radioligands would be useful for exploring the roles that NOP receptors may play in human health and disease where relevant animal models showed changes. In addition, an NOP receptor radioligand could help determine the therapeutic mechanisms of some opiates; buprenorphine, for

Received Aug. 18, 2011; revision accepted Nov. 3, 2011.

For correspondence contact: Robert B. Innis, Molecular Imaging Branch, National Institute of Mental Health, 10 Center Dr., Bethesda, MD 20892-1026. E-mail: robert.innis@nih.gov

Published online Feb. 6, 2012.

COPYRIGHT © 2012 by the Society of Nuclear Medicine, Inc.

example, is used to treat both pain and heroin dependence and may act on NOP and other opiate receptors (6). Finally, a PET radioligand for the NOP receptor would aid in the early evaluation of potential therapeutic NOP receptor agonists and antagonists. Such early studies could determine receptor occupancy and clarify required dose and dosing intervals, which are often critically important for the development of drugs that may have restricted access to brain because of the blood–brain barrier and efflux transporters.

Our laboratory developed ^{11}C -NOP-1A, which is to our knowledge the first successful radioligand to image NOP receptors in rat and monkey brain (7). ^{11}C -NOP-1A is a selective antagonist at the NOP receptor and has high affinity and appropriate lipophilicity for blood–brain barrier permeability. ^{11}C -NOP-1A imaging in rhesus monkeys showed high brain uptake and a large receptor-specific signal and could be quantified with the gold standard method of compartmental modeling (8).

The present study sought to determine whether ^{11}C -NOP-1A could image and quantify NOP receptor distribution in the living human brain at a dose safe for human subjects. To evaluate how well uptake could be quantified relative to the amount of radioligand delivered to the brain, we imaged the brain and measured serial arterial blood samples after injecting ^{11}C -NOP-1A. We further imaged the whole body to measure radioactivity in identifiable organs and to estimate radiation exposure to the whole body.

MATERIALS AND METHODS

Radioligand Preparation

^{11}C -NOP-1A was labeled by ^{11}C -methylation of an *N*-desmethyl precursor, as previously described (7). The radioligand was prepared according to our exploratory Investigational New Drug Application (109077), which has been submitted to the U.S. Food and Drug Administration and a copy of which is available at <http://pdsp.med.unc.edu/snidd/IND/nop1a.html>. The radioligand was obtained with high radiochemical purity (>99%) and a specific activity of 213 ± 100 GBq/ μmol at the time of injection ($n = 16$ batches).

Subjects

Seven healthy volunteers participated in the brain PET scans (4 men and 3 women; 33 ± 7 y old). Nine separate healthy volunteers participated in the whole-body PET scans (5 men and 4 women; 31 ± 9 y old). All subjects were free of current medical or psychiatric illnesses, as determined by medical history, physical examination, electrocardiogram, urinalysis including drug screening, and laboratory blood tests (complete blood count, serum chemistries, and thyroid function test). Each subject's vital signs were recorded before ^{11}C -NOP-1A injection and at 15, 30, 90, and 120 min after injection. Urinalysis and blood tests were repeated within 2 h of PET scan completion.

Measurement of ^{11}C -NOP-1A in Plasma

To determine arterial input function for brain PET scans, blood samples (1.5 mL each) were drawn from the radial artery at 15-s intervals until 150 s, followed by 3-mL samples at 3, 4, 6, 8, 10, 15, 20, 30, 40, and 50 min, and 5-mL samples at 60, 75, 90, and

120 min. The concentration of parent radioligand was measured as previously described (7).

A metabolite-corrected plasma input function was obtained as follows: the time–activity curves of total radioactivity in plasma and whole blood were fitted to a triexponential function with Poisson weighting of the actual radioactivity counts detected in plasma and whole blood, respectively. The ^{11}C -NOP-1A parent fraction measured in the plasma samples was fitted to a Hill function with Poisson weighting of the area under the curve of parent peaks from the radiochromatogram. The fitted total plasma radioactivity was multiplied by the Hill function–fitted parent fraction to obtain the metabolite-corrected plasma input function.

The plasma free fraction was measured by ultrafiltration, as previously described (9). Radioactivity in whole blood was used to correct radioactivity in brain that represents the vascular compartment (~5% of tissue volume). All plasma data are mean \pm SD from 7 healthy subjects.

PET Scans

All PET scans were performed on an Advance tomograph (GE Healthcare). For brain scans, ^{11}C -NOP-1A (716 ± 83 MBq) was intravenously injected over 1 min and dynamic 3-dimensional emission scans were acquired for 120 min in 33 frames of increasing duration from 30 s to 5 min. One brain transmission scan using ^{68}Ge rods was acquired before the injection of the radioligand. Head movement was corrected after the scan by realigning all frames from each subject using Statistical Parametric Mapping (SPM, version 8 for Windows; Wellcome Department of Cognitive Neurology). The position of the transmission scan was corrected for motion before attenuation correction was applied. For whole-body scans, ^{11}C -NOP-1A (675 ± 187 MBq) was intravenously injected over 20 s and dynamic 2-dimensional emission scans were acquired for approximately 120 min in 14 frames by serial imaging of the body in 7 contiguous segments. The frame duration and transmission scans were conducted as previously described (10).

Brain Image Analysis

The averaged PET image was created by averaging all frames of the PET images. The averaged PET image was then coregistered to each subject's MR image using a 6-parameter algorithm in SPM. Sagittal MR images of 1-mm contiguous slices were obtained using a 3.0-T Achieva device (Philips Health Care) with a repetition time of 8.1 ms, an echo time of 3.7 ms, and a flip angle of 8° . All MR and PET images were then spatially normalized to Montreal Neurologic Institute space using transformation parameters from the MR images. A template of preset volumes of interest (VOIs) (11) was applied to the spatially normalized PET images to extract time–activity curves for the following 10 regions: frontal (432 cm 3), parietal (247 cm 3), occipital (172 cm 3), temporal (251 cm 3), and medial temporal (36 cm 3) cortices; caudate (16 cm 3); putamen (17 cm 3); cingulate (28 cm 3); thalamus (17 cm 3); and cerebellum (195 cm 3). Image and kinetic analyses were performed using pixelwise modeling software (PMOD, version 3.16; PMOD Technologies Ltd.).

Calculation of Distribution Volume (V_T)

V_T is an index of receptor density and equals the ratio at equilibrium of the concentration of radioligand in tissue to that in plasma. The concentration of radioligand in tissue represents the sum of specific binding (receptor-bound) and nondisplaceable uptake (nonspecifically bound and free radioligand in tissue water) (12). The equilibrium value of V_T was calculated 3 different ways to assess whether the methods applicable to voxel data yielded V_T

values similar to those obtained by the VOI data using the gold standard method of compartmental modeling.

Compartmental Modeling. Brain time–activity data were analyzed with both 1- and 2-tissue-compartment models. Rate constants (K_1 , k_2 , k_3 , and k_4) in standard 1- and 2-tissue-compartment models were estimated with the weighted least-squares method and the Marquardt optimizer. Brain data for each frame were weighted by assuming that the SD of the data was proportional to the inverse square root of noise equivalent counts. To correct the brain data for the vascular component, radioactivity in serial whole blood was measured and subtracted from the PET measurements, assuming that cerebral blood volume is 5% of total brain volume. The delay between the arrival of $^{11}\text{C-NOP-1A}$ in the radial artery and brain was estimated by fitting the whole brain, excluding the white matter.

Linear and Multilinear Graphical Analyses. The graphical approach of Logan (13), a linear regression method with input function that does not specify a particular compartmental configuration, was used to calculate V_T . With the maximum deviation between the regression and all measurements set to 20%, the equilibration start time and the slope of the linear portion of the Logan plot (V_T) were fitted for each brain region that included data from multiple voxels within a VOI. To decrease the bias induced by noise in the measurements, V_T was also calculated by Ichise's bilinear analysis, MA1 (14), using the same start time as that obtained from the Logan analysis for each brain region that included data from multiple voxels within a VOI.

Parametric Imaging. To determine whether V_T could be determined from the voxel data, voxelwise parametric images of V_T ($\text{Logan}_{\text{voxel}}$ and $\text{MA1}_{\text{voxel}}$) were generated using data from each voxel of dynamic PET images. For both Logan and MA1 methods, PET frames used for the regression were selected on the basis of start time obtained from the time–activity curve of whole brain excluding white matter and by setting the maximum deviation between the regression and all measurements to 20%. The same plasma input function as that used for compartmental modeling was used for the parametric modeling.

Time Stability Analysis

To determine the minimal scan length for reliable measurements and to indirectly assess whether $^{11}\text{C-NOP-1A}$ radiometabolites enter brain, time stability of V_T was examined by increasingly truncating the scan duration from 0–120 min to 0–40 min in 10-min increments.

Dosimetry Analysis

Source organs were identified on the individual transaxial slices of whole-body PET images. The frames with the highest organ uptakes were averaged and smoothed by a gaussian filter to increase the contrast between the organ and surrounding tissue. Brain, lungs, heart, liver, kidneys, gallbladder, urinary bladder, pancreas, and thyroid were identified as the source organs.

Uptake in each source organ was corrected for recovery of measured activity, which was calculated by averaging the activity of the second through sixth frames with a large region of interest placed over the entire body visible by PET. Recovery averaged $87\% \pm 4\%$ for all subjects ($n = 9$).

At each time point, the measured activity (i.e., not corrected for decay) of the source organ was expressed as percentage injected activity (%IA). The area under the time–activity curve of each organ was calculated by the trapezoidal method until scan acquisition ended. The area after the last image to infinity was calculated by

assuming that the subsequent decline of radioactivity occurred by only physical decay, without any further biologic clearance. The area under the curve of %IA from time zero to infinity equals the residence time of the organ. To calculate the residence time for the remainder of the body, the residence times for all source organs were summed and subtracted from the fixed theoretic value of half-life/ $\ln 2 = 0.49$ h.

Radiation absorbed doses were calculated according to the MIRD scheme using OLINDA/EXM 1.1 (<http://www.doseinfo-radar.com/OLINDA.html>) using the model for a 70-kg adult male.

Statistical Analysis

The optimal compartment model (i.e., 1 vs. 2 tissue compartments) was chosen on the basis of the Akaike information criterion, model selection criterion, and F test (15). The most appropriate model would be the one with the smallest Akaike information criterion and the largest model selection criterion value. F statistics were used to compare goodness of fit by 1- and 2-tissue-compartment models. A value of P less than 0.05 was considered significant. The identifiability of V_T was expressed as a percentage and equaled the ratio of the SE of V_T divided by the value of V_T itself. A lower percentage indicates better identifiability.

For each subject, using simple regression we compared regional brain V_T values by Logan and MA1 methods obtained from VOI and voxel data, and the V_T values obtained from the gold standard method of 2-tissue-compartment model applied to VOI data. To compare the difference in V_T between different methods, we applied repeated-measures ANOVA for V_T values in the regions. All statistical analyses were performed with SPSS (version 17 for Windows; SPSS Inc.). Group data are expressed as mean \pm SD. The mean and SD for parametric images were calculated in each voxel across subjects, and then values from all voxels were averaged within each VOI.

RESULTS

Pharmacologic Effects

The injected mass dose of $^{11}\text{C-NOP-1A}$ was 53 ± 36 pmol/kg ($n = 16$). This dose caused no pharmacologic effects in any subject during the 2-h PET scan, nor did it affect blood pressure, pulse, respiratory rate, electrocardiogram, or pulse oximetry. Similarly, no significant effects were noted in any of the blood or urine tests acquired at the end of the scan.

Plasma Analysis

$^{11}\text{C-NOP-1A}$ concentrations in arterial plasma peaked to 13 ± 4 standardized uptake values (SUVs) at 75 s after $^{11}\text{C-NOP-1A}$ injection and then rapidly declined, followed by a slow terminal clearance phase. The fraction of $^{11}\text{C-NOP-1A}$, expressed as a percentage of total plasma radioactivity, declined rapidly and reached $52\% \pm 12\%$ at 15 min followed by a gradual decline (Supplemental Fig. 1). The fitting of whole blood and total plasma curves converged by triexponential function, and that of parent fraction curve converged by Hill function in all subjects. Figure 1A shows the measured and fitted parent fraction curves, and Figure 1B shows the parent concentration and fitting in a single subject.

Radiometabolites appeared quickly in the plasma and, after 20 min, became the predominant component of plasma radioactivity. All radiometabolites eluted before the more lipophilic parent but were not well resolved by




FIGURE 1. Parent radioligand fraction, radioactivity concentrations (conc), and radiometabolite profile in plasma from 40-y-old healthy man injected with 755 MBq of ^{11}C -NOP-1A. (A) Fraction of unchanged parent radioligand ^{11}C -NOP-1A (\circ) in plasma fitted by Hill function. (B) Time course of parent ^{11}C -NOP-1A concentration (\circ) in arterial plasma fitted by multiplying triexponential-fitted total plasma radioactivity and Hill function-fitted plasma parent fraction. (C) Radiochromatogram illustrating plasma composition 40 min after injection of ^{11}C -NOP-1A. Radioactivity was measured in counts per second (cps). Peaks A to D and parent are labeled with increasing lipophilicity.

reverse-phase high-performance liquid chromatography (Fig. 1C). The parent radioligand eluted at 5 min and was well separated from the rest of the radiometabolites.

The plasma free fraction and clearance of ^{11}C -NOP-1A were $10.1\% \pm 1.7\%$ ($n = 7$) and $1.2 \pm 0.3 \text{ L/min}$ ($n = 7$), respectively.

Brain Radioactivity and Kinetic Analysis

After ^{11}C -NOP-1A injection, all subjects showed high concentrations of radioactivity followed by quick washout in all brain regions. Radioactivity in brain peaked to approximately 5–7 SUVs at about 10 min and decreased to 50% of the peak by about 50 min (Supplemental Fig. 2). Consistent with the distribution of ^3H -nociceptin binding in postmortem human brain (16), the in vivo distribution of radioactivity was widespread in brain, with moderate levels in all areas of neocortex, highest in putamen, and lowest in cerebellum (Fig. 2). Because no brain region lacks NOP expression, we did not apply a reference region method in the kinetic analysis.

The kinetic analysis of brain and plasma data had 4 major results. First, the brain time–activity curves from VOI data fitted better with an unconstrained 2- than a 1-tissue-compartment model. Second, Logan and MA1 analyses using both VOI- and voxel-based methods could determine V_T but significantly underestimated it compared with a 2-tissue-compartment model. Third, although the $\text{MA1}_{\text{voxel}} V_T$ was significantly lower than the 2-tissue-compartment model V_T , $\text{MA1}_{\text{voxel}} V_T$ values across regions correlated well with 2-tissue V_T and were significantly higher than $\text{Logan}_{\text{voxel}} V_T$. Fourth, 70-min data adequately measured V_T .

With regard to the first result, unconstrained 2-tissue-compartment fitting converged in all regions and in all scans. An F test showed that the 2-tissue-compartment model was superior to the 1-tissue-compartment model in all 60 fittings in a total of 6 scans (Fig. 3), indicating the presence of significant amounts of both specific and nonspecific binding in human brain. In addition, the 2-tissue-compartment model showed lower mean Akaike information criterion scores (93

vs. 173) and higher mean model selection criterion scores (7.4 vs. 4.9) than the 1-tissue-compartment model. One scan showed significantly better fit in all regions by 1- than 2-tissue-compartment model as determined by F test, Akaike information criterion, and model selection criterion scores. The unconstrained 2-tissue-compartment model identified V_T with average SE of 1.1% across brain regions. Regional values of 2-tissue V_T ($\text{mL}\cdot\text{cm}^{-3}$) ranged from 10.1 in temporal cortex to 5.6 in cerebellum. The rate constants K_1 and k_2 were relatively well identified, with a median SE of less than 10% across all regions, whereas the rate constants k_3 and k_4 were poorly identified, with median SEs of more than 10% across all regions (Supplemental Table 1).

As regards the second result, V_T was also calculated using the Logan graphical approach (Supplemental Fig. 3) and MA1, as well as voxel-based Logan and MA1 models. The 2-tissue V_T provided the highest estimates of V_T across all brain regions (Table 1). Logan and MA1 models from both




FIGURE 2. MRI and MA1 parametric PET images of 44-y-old healthy man injected with 738 MBq of ^{11}C -NOP-1A: MRI anatomic images (A) and MA1 parametric images (B) in axial (left), sagittal (middle), and coronal (right) views. Each pixel value represents V_T and is indicated in V_T color scale on right.




FIGURE 3. Representative brain uptake with compartmental fitting from 40-y-old healthy man injected with 755 MBq of ^{11}C -NOP-1A. Concentration of radioactivity from 3 regions is shown: putamen (○), with highest uptake; cingulate cortex (●), with medium uptake; and cerebellum (□), with lowest uptake. Line represents unconstrained 2-tissue-compartment fitting.

VOI- and voxel-based methods significantly (all $P < 0.05$) underestimated V_T in all subjects (factorial repeated-measures ANOVA using Bonferroni adjustment, $F_{2,35,14,10} = 93.11$), but intersubject variability was similar among different methods. The mean difference in V_T was highest between 2-tissue and $\text{Logan}_{\text{voxel}}$ (1.06) models. V_T estimated by $\text{MA1}_{\text{voxel}}$ was significantly higher ($P < 0.05$) than that estimated by $\text{Logan}_{\text{voxel}}$ model, with a mean difference of 0.45 (Fig. 4A).

As regards the third result, $\text{MA1}_{\text{voxel}}$ V_T significantly correlated with 2-tissue V_T for all subjects (Fig. 4B). The Pearson R^2 for brain regions without cerebellum ranged from 0.94 to 1.0 ($P < 0.001$). The nonparametric Spearman ρ for brain regions with cerebellum ranged from 0.89 to 1.0 ($P < 0.001$). Figure 3 displays parametric images of V_T ($\text{MA1}_{\text{voxel}}$) from a single subject.

Finally, V_T values were stable from 70 to 120 min and were well identified (SE < 10%) using only 70-min data (Supple-

mental Fig. 4), indicating negligible accumulation of radiometabolites and suggesting that 70 min of scan data are adequate to calculate V_T .

Whole-Body Biodistribution and Dosimetry Estimates

Whole-body images were notable for early distribution of radioactivity in the blood pool, accumulation in the target organ (i.e., brain), and excretion via hepatobiliary and urinary routes (Figs. 5 and 6). At early time points, radioactivity was prominent in organs with high blood volume, including heart, kidneys, spleen, and thyroid. Consistent with its high density of NOP receptors, the brain had high radioactivity uptake, with a peak of about 11 %IA at 8–10 min after ^{11}C -NOP-1A injection. The images showed that radioactivity was excreted via both hepatobiliary and urinary routes (with about 7 %IA in gallbladder and about 6 %IA in urinary bladder by the end of the scan). In addition, radioactivity was prominent in heart and pancreas, with a peak of about 1.4 and 1.5 %IA at 8–10 min. The spleen also showed high radioactivity uptake, with a peak of about 2.5 %IA at 2 min.

The 3 source organs with the longest residence time of radioactivity were liver, brain, and lungs (Supplemental Table 2). The 3 organs with the highest estimates of radiation exposure ($\mu\text{Sv}/\text{MBq}$) were gallbladder wall (21.4 ± 10.1), pancreas (16.3 ± 7.5), and kidneys (12.2 ± 1.6) (Supplemental Table 3). The effective dose, which is a weighted sum of overall exposure to the organs, was $4.3 \pm 0.2 \mu\text{Sv}/\text{MBq}$ ($15.8 \pm 0.9 \text{ mrem}/\text{mCi}$).

DISCUSSION


To our knowledge, this study was the first to investigate the imaging and quantification of NOP receptors in living human brain. Using ^{11}C -NOP1A, we found that radioactivity uptake in brain was high and stably quantified as total V_T , reflecting the density of the receptors. Using metabolite-corrected arterial input function, V_T was well quantified, with high identifiability (i.e., low SE) by the gold standard method of 2-tissue-compartment kinetic modeling.

TABLE 1
Regional V_T of ^{11}C -NOP-1A in Human Brain Determined from Large VOIs or from Individual Voxels

Brain region	V_T (mL cm^{-3})				
	VOI			Voxel	
	Two-tissue	$\text{Logan}_{\text{VOI}}$	MA1_{VOI}	$\text{Logan}_{\text{voxel}}$	$\text{MA1}_{\text{voxel}}$
Temporal cortex	10.1 ± 1.6	9.6 ± 1.6	9.5 ± 1.5	8.9 ± 1.7	9.4 ± 1.8
Cingulate cortex	9.4 ± 1.5	8.9 ± 1.5	8.9 ± 1.5	8.3 ± 1.5	8.8 ± 1.6
Putamen	10.0 ± 1.8	9.5 ± 1.7	9.4 ± 1.7	8.9 ± 1.7	9.3 ± 1.8
Thalamus	9.0 ± 1.6	8.5 ± 1.5	8.5 ± 1.5	8.0 ± 1.6	8.5 ± 1.6
Cerebellum	5.6 ± 0.8	5.2 ± 0.8	5.3 ± 0.8	4.8 ± 1.0	5.1 ± 1.0

Values are mean \pm SD from 7 humans using 120 min of brain and plasma data. Two-tissue-compartment model was fit with no constraints. Subscript “VOI” denotes that concentration of radioactivity from large VOIs (e.g., entire temporal cortex of 251 cm^3) was analyzed. Subscript “voxel” denotes that concentration of radioactivity of individual voxel (8 mm^3) was analyzed. Voxels of resulting parametric image have values equal to V_T .

FIGURE 4. Comparison of total V_T in various brain regions. V_T values were calculated in 7 subjects injected with ^{11}C -NOP-1A using unconstrained 2-tissue-compartment model for VOI data and Logan and MA1 methods for voxel data (Logan $_{\text{voxel}}$ and MA1 $_{\text{voxel}}$). (A) Mean V_T values obtained by both MA1 $_{\text{voxel}}$ (hatched bars) and Logan $_{\text{voxel}}$ (white bars) were significantly lower than those obtained by 2-tissue-compartment model (black bars) ($P < 0.05$ by factorial repeated-measures ANOVA). Logan $_{\text{voxel}}$ gave significantly smaller V_T values than MA1 $_{\text{voxel}}$ ($P < 0.05$). Data represent mean \pm SD of all 7 subjects. (B) Scatterplot comparing mean V_T values from each region (excluding cerebellum) by MA1 $_{\text{voxel}}$ method vs. 2-tissue-compartment model in 40-y-old healthy man injected with 755 MBq of ^{11}C -NOP-1A. Simple linear regression was significant (Pearson $R^2 = 0.95$, $P < 0.0001$), with linear regression line equation $y = 1.05x + 0.1$. Solid line represents line of best fit. Dashed lines are 95% confidence intervals. FC = frontal cortex; PA = parietal cortex; OC = occipital cortex; TC = temporal cortex; MT = medial temporal cortex; CC = cingulate cortex; CA = caudate cortex; PU = putamen; TH = thalamus; CE = cerebellum.



V_T determined from the voxel-based MA1 method correlated well with the results from a 2-tissue-compartment model, indicating that parametric methods could be used for quantification in population studies. Whole-body scans of ^{11}C -NOP-1A showed that the effective dose to humans was $4.3 \mu\text{Sv}/\text{MBq}$, which is similar to the effective dose of other ^{11}C -labeled radioligands.

After the discovery of the NOP receptor in 1994 and its endogenous ligand NOP a year later, numerous peptide and nonpeptide ligands targeting the NOP receptor were developed. However, until now, no promising radioligands had been developed capable of imaging NOP receptors in vivo in humans. Two radioligands developed by Ogawa et al. (17,18)— ^{11}C -methyl-Ro 64-6198 and ^{11}C -CPEB—had high affinity for NOP receptors in rat brain, but they also had high nonspecific binding, making them unsuitable for PET. In comparison, initial trials with our radioligand, ^{11}C -NOP-1A, dem-

onstrated a selective and displaceable binding with high affinity at NOP receptors in rats and monkeys (7,8).

We found that radioactivity in human brain was high after ^{11}C -NOP-1A injection, followed by a quick washout from all brain regions. Notably, high uptake and quick washout from brain enable the quantification of brain uptake by compartmental modeling, given that the kinetics of the radioligand reflect association and dissociation binding to the target receptor. Both 1- and 2-tissue-compartment models successfully identified V_T with a low SE. However, statistical analysis showed that the 2-tissue-compartment model provided a significantly better fit in most scans, consistent with both specific and nonspecific compartments in brain. Interestingly, our previous studies of ^{11}C -NOP-1A in monkey brain had shown that the 1-tissue-compartment model provided a better fit than the 2-tissue model. In addition, V_T values from brain regions were nearly 2-fold




FIGURE 5. Whole-body images of healthy 22-y-old man show distribution of radioactivity at about 6, 50, and 102 min after injection of 480 MBq of ^{11}C -NOP-1A. In addition to high uptake in brain, image at 6 min shows high uptake in lungs and heart. Images at 50 and 102 min show excretion of radioactivity via liver, small bowel, and urinary bladder. These images were created by summing all coronal slices at each time point. Pixel values were decay-corrected to time of injection and displayed with same gray scale.




FIGURE 6. Time-activity curves for 10 source organs after ^{11}C -NOP-1A injection. Data are corrected for radioactive decay and expressed as mean and SD (symbol and error bars) from 9 subjects.

higher in monkeys than in humans. Changes in plasma free fraction between species can cause the difference in V_T values, but the plasma free fraction of ^{11}C -NOP-1A in monkeys ($11.3\% \pm 1.1\%$ (7)) and humans ($10.1\% \pm 1.7\%$ [data from this study]) were similar. The sources of these differences are unclear, but possibilities include anesthesia, different proportions of gray and white matter, and different ratios of specific-to-nondisplaceable binding.

We further found that the Logan parametric method significantly underestimated V_T compared with the gold standard 2-tissue-compartment model, because the Logan method is vulnerable to low counts—and hence noise—in the imaging data. Despite a slight underestimation, V_T determined using the MA1 parametric method correlated well with that of the 2-tissue-compartment model, indicating that the MA1 parametric method measured ^{11}C -NOP-1A binding in brain in a manner comparable to the 2-tissue-compartment model. The small underestimate observed with the MA1 parametric method was significantly less than that observed with the Logan parametric method, specifically because the MA1 method reduces the magnitude of noise-induced bias compared with the Logan method (14). As a result, parametric methods such as MA1 can be used for SPM analyses to compare populations.

The effective dose of ^{11}C -NOP-1A ($4.3 \mu\text{Sv}/\text{MBq}$) estimated from whole-body scans in humans was similar to previous estimates ($5 \mu\text{Sv}/\text{MBq}$) from monkey studies (8) and to those of 34 other ^{11}C -radioligands used for brain imaging, which ranged from 3 to $16 \mu\text{Sv}/\text{MBq}$ (19). The whole-body scans showed notable accumulation of radioactivity in peripheral organs such as heart, spleen, and pancreas. The radioactivity localization in these organs was confirmed by a PET/CT scan in a healthy subject (Supple-

mental Fig. 5). NOP receptors are known to be present in human heart (20) and spleen, an organ rich in immune cells (21). Functional studies in exocrine pancreas of guinea pig indicated the presence of NOP receptors in pancreatic lobules (22). Thus, uptake in those organs may represent receptor-specific binding. Further research is necessary to verify NOP receptor-specific binding in peripheral organs.

^{11}C -NOP-1A has many positive attributes as a PET radioligand, including its short half-life of ^{11}C (20.4 min), which allows a subject to participate in 2 studies per day (e.g., to study treatment effects under identical conditions to reduce variability). Nevertheless, it also has at least 3 relative limitations. First, the short half-life of ^{11}C requires the availability of a cyclotron at the site of radioligand administration. Labeling with longer-lived ^{18}F (half-life, 109.7 min) would be more useful, since that would allow central production and distribution to distant PET centers. Future developments in labeling radiotracers with no-carrier-added cyclotron-produced ^{18}F -fluoride ions, and in particular the use of diaryliodonium salts as precursors, might permit NOP-1A to be labeled in 1 step in its aryl fluoro position, thereby facilitating such applications (23,24).

A second limitation of ^{11}C -NOP-1A is that a reference region in brain may not exist. ^{11}C -NOP-1A blockade studies in monkeys found that all regions of brain, including cerebellum—a low-binding region—had specific binding, suggesting a lack of reference region in brain. Displacement and blockade studies are needed in humans to assess whether this is also true in the larger human brain and to identify any reference region. Reference region identification would allow the use of image quantification by reference tissue models without invasive arterial blood sampling.

A third limitation is that because ^{11}C -NOP-1A is an antagonist, it is likely insensitive to displacement by the

endogenous agonist of the NOP receptor. For example, ¹¹C-carfentanil, a highly specific μ -opioid receptor agonist, is displaced by endogenous opioids after a painful stimulus (25). Animal studies are needed to determine whether a significant proportion of NOP receptors is coupled to G-proteins or is even sensitive to agonists. For example, in the case of the CB₁ receptor, most of the receptors appear to be in low affinity, G-protein-uncoupled states, thus making them unsuitable for binding with an agonist radioligand (26). In such cases, an antagonist such as ¹¹C-NOP-1A is favored over an agonist, given that an antagonist binds to the receptor with equal affinity and is not affected by the affinity status of the receptor.

CONCLUSION

Our results demonstrated that ¹¹C-NOP-1A reliably quantified NOP receptors in human brain both in large brain regions and at a voxelwise level using parametric imaging. The radiation absorbed dose in humans was similar to that observed with other ¹¹C-labeled ligands and would allow multiple scans of a single subject. Thus, ¹¹C-NOP-1A is a promising radioligand for reliably quantifying NOP receptors in human brain. This, in turn, makes it a potential candidate to study the role of NOP receptors in disorders such as drug abuse and anxiety and to facilitate the development of therapeutic drugs at this target site.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

ACKNOWLEDGMENTS

This study was supported by the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH), and by a Cooperative Research and Development Agreement with Eli Lilly & Co. We thank Denise Rallis-Frutos, Gerald L. Hodges, Kimberly Jenko, David Clark, Jeh-San Liow, Robert L. Gladding, and the staff of the PET Department for assistance in successful completion of the studies, and PMOD Technologies (Zurich, Switzerland) for providing its image analysis and modeling software. Ioline Henter provided invaluable editorial assistance. No other potential conflict of interest relevant to this article was reported.

REFERENCES

- Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. *FEBS Lett*. 1994;341:33–38.
- Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. *Nature*. 1995;377:532–535.
- Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. *Nat Rev Drug Discov*. 2008;7:694–710.
- Economidou D, Hansson AC, Weiss F, et al. Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. *Biol Psychiatry*. 2008;64:211–218.
- Varty GB, Hyde LA, Hodgson RA, et al. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. *Psychopharmacology (Berl)*. 2005;182:132–143.
- Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. *Biol Psychiatry*. 2007;61:4–12.
- Pike VW, Rash KS, Chen Z, et al. Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. *J Med Chem*. 2011;54:2687–2700.
- Kimura Y, Fujita M, Hong J, et al. Brain and whole-body imaging in rhesus monkeys of ¹¹C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. *J Nucl Med*. 2011;52:1638–1645.
- Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. *J Pharm Sci*. 1994;83:1014–1019.
- Brown AK, Fujita M, Fujimura Y, et al. Radiation dosimetry and biodistribution in monkey and man of ¹¹C-PBR28: a PET radioligand to image inflammation. *J Nucl Med*. 2007;48:2072–2079.
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002;15:273–289.
- Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. *J Cereb Blood Flow Metab*. 2007;27:1533–1539.
- Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [¹¹C-methyl]-(-)-cocaine PET studies in human subjects. *J Cereb Blood Flow Metab*. 1990;10:740–747.
- Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. *J Cereb Blood Flow Metab*. 2002;22:1271–1281.
- Fujita M, Seibyl JP, Verhoeff NP, et al. Kinetic and equilibrium analyses of [¹²³I]epidepride binding to striatal and extrastriatal dopamine D₂ receptors. *Synapse*. 1999;34:290–304.
- Berthelè A, Platzer S, Dworzak D, et al. [³H]-nociceptin ligand-binding and nociceptin opioid receptor mRNA expression in the human brain. *Neuroscience*. 2003;121:629–640.
- Ogawa M, Hatano K, Kawasumi Y, et al. Synthesis and evaluation of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[¹¹C]methyl-1,3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography. *Nucl Med Biol*. 2003;30:51–59.
- Ogawa M, Hatano K, Kawasumi Y, Wichmann J, Ito K. Synthesis and in vivo evaluation of [¹¹C]methyl-Ro 64-6198 as an ORL1 receptor imaging agent. *Nucl Med Biol*. 2001;28:941–947.
- Hines CS, Liow J-S, Zanotti-Fregonara P, et al. Human biodistribution and dosimetry of ¹¹C-CUMI-101, an agonist radioligand for serotonin-1A receptors in brain. *PLoS ONE*. 2011;6:e25309.
- McDonald J, Leonard AD, Serrano-Gomez A, et al. Assessment of nociceptin/orphanin FQ and micro-opioid receptor mRNA in the human right atrium. *Br J Anaesth*. 2010;104:698–704.
- Arjomand J, Cole S, Evans CJ. Novel orphanin FQ/nociceptin transcripts are expressed in human immune cells. *J Neuroimmunol*. 2002;130:100–108.
- Linari G, Agostini S, Broccardo M, Petrella C, Improta G. Regulation of pancreatic secretion in vitro by nociceptin/orphanin FQ and opioid receptors: a comparative study. *Pharmacol Res*. 2006;54:356–360.
- Cai LS, Lu SY, Pike VW. Chemistry with [¹⁸F]fluoride ion. *Eur J Org Chem*. 2008;2853–2873.
- Chun JH, Lu SY, Lee YS, Pike VW. Fast and high-yield microreactor syntheses of ortho-substituted [¹⁸F]fluoroarenes from reactions of [¹⁸F]fluoride ion with diaryliodonium salts. *J Org Chem*. 2010;75:3332–3338.
- Bencherif B, Fuchs PN, Sheth R, Dannals RF, Campbell JN, Frost JJ. Pain activation of human supraspinal opioid pathways as demonstrated by [¹¹C]-carfentanil and positron emission tomography (PET). *Pain*. 2002;99:589–598.
- Terry G, Liow JS, Chernet E, et al. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. *Neuroimage*. 2008;41:690–698.